Physician profile
Anu Saji
NPI 1558932970
$4,656.27
in general payments reported to CMS, 2019-2025
28 companies · $2,427 in 2025
The $2,427 reported for 2025 was more than what 95% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $120 · 2022: $309 · 2023: $274 · 2024: $1,526 · 2025: $2,427.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,903 · Education: $324.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,902.73 |
| Education | $324.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $674.43 | 2024-2025 | Impella |
| Amgen INC. | $518.29 | 2024-2025 | Repatha, Repatha |
| E.R. Squibb & Sons, L.L.C. | $405.76 | 2022-2025 | Camzyos, Opdivo, Eliquis |
| Abbott Laboratories | $372.07 | 2024-2025 | Ensite, Cardiomems |
| Boehringer Ingelheim Pharmaceuticals, INC. | $359.12 | 2021-2025 | Jardiance |
| Astrazeneca Pharmaceuticals Lp | $238.58 | 2022-2025 | Farxiga, Lokelma |
| Shockwave Medical, INC | $197.31 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Pfizer INC. | $187.05 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $175.04 | 2022-2025 | |
| Esperion Therapeutics, INC. | $170.54 | 2024-2025 | Nexletol |
| Actelion Pharmaceuticals US, INC. | $163.58 | 2024-2025 | Opsumit, Uptravi |
| Heartflow, INC. | $147.26 | 2025 | |
| Alnylam Pharmaceuticals INC. | $109.47 | 2025 | Amvuttra, Onpattro |
| Novartis Pharmaceuticals Corporation | $98.85 | 2024-2025 | |
| Lexicon Pharmaceuticals, INC. | $81.99 | 2024 | Inpefa |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lantheus Medical Imaging, INC. | $78.35 | 2024-2025 | |
| Gilead Sciences, INC. | $75.62 | 2021 | |
| Penumbra, INC. | $70.52 | 2025 | Indigo System |
| Boston Scientific Corporation | $70.22 | 2024-2025 | Watchman Flx, Avvigo Guidance System, Accolade Sr |
| Kiniksa Pharmaceuticals International, Plc | $69.82 | 2024 | Arcalyst |
| Medtronic, INC. | $69.35 | 2024-2025 | Azure Xt Dr Mri Surescan, Linq II |
| Novo Nordisk INC | $62.68 | 2024 | Ozempic, Rybelsus |
| Alexion Pharmaceuticals, INC. | $62.51 | 2022-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $48.46 | 2023-2025 | Entyvio |
| Abbvie INC. | $45.22 | 2023 | Teflaro, Avycaz, Dalvance |
| Scpharmaceuticals INC. | $43.71 | 2024-2025 | |
| Viiv Healthcare Company | $31.67 | 2023 | Dovato |
| Bridgebio Pharma, INC. | $28.80 | 2025 | Attruby |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anu Saji listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.